Neoadjuvant chemoimmunotherapy
Phase 3Small molecule
Neoadjuvant chemoimmunotherapy is one of 46 small molecule programs targeting Esophageal Squamous Cell Carcinoma (ESCC). It is currently in Phase 3.
2
Indications
4
Total Trials
4
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Locally-Advanced Rectal Cancer
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Beyfortus
BeiGenePhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
FOLFOX
AstraZenecaPhase 3
Camptosar
PfizerPhase 2
Avastin
RochePhase 2
Mfolfirinox
IncytePhase 3
Keytruda
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally-advanced Rectal Cancer1 trial
Esophageal Squamous Cell Carcinoma1 trial
Non-small Cell Carcinoma1 trial
Esophageal Squamous Cell Carcinoma (ESCC)1 trial
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II Clinical Study
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07721103·110 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZhejiang Cancer Hospital